利福平可抑制转运对大鼠厄洛替尼肝脏分布及组织动力学的影响:PET显像评估
在大鼠中利用PET显像研究利福平(40 mg/kg)对11C-厄洛替尼肝脏摄取及组织暴露的影响。利福平未改变腹主动脉AUC,但使肝脏暴露显著降低27.3%(p < 0.001),肾脏AUC降低30.4%(p < 0.001),肺摄取及暴露均未受影响。结果提示11C-厄洛替尼在体内是肝脏rOATP转运体的底物,可能也是肾脏中利福平可抑制转运体的底物。
要点
- 利福平使大鼠肝脏11C-厄洛替尼暴露降低27.3%(p < 0.001),摄取速率常数kuptake亦降低。
- 利福平使大鼠肾脏AUC降低30.4%(p < 0.001),肾脏kuptake亦降低。
- 利福平未影响腹主动脉AUC、肺kuptake及肺AUC。
核心结论
- 结果提示11C-厄洛替尼在体内是肝脏表达的rOATP转运体底物,可能也是肾脏中利福平可抑制转运体的底物。
- 消除器官对11C-厄洛替尼摄取的降低未转化为全身暴露及肺暴露(肺为厄洛替尼治疗靶组织)的改变。
研究设计与样本
- 大鼠研究,每组4只动物,使用PET显像评估利福平(40 mg/kg)对11C-厄洛替尼肝脏摄取及组织动力学的影响。
- 评估肝脏、肾皮质、腹主动脉(血池)及肺的组织药代动力学与相应暴露(AUC),并通过动脉血采样测定11C-厄洛替尼血浆药代动力学以估算从血浆进入不同组织的转运速率常数(kuptake)。
主要发现
- PET图像显示11C-厄洛替尼相关放射性主要分布于肝脏,并逐渐向肠道移动,提示肝胆清除。
- 11C-厄洛替尼亦在肾皮质中蓄积。
- 利福平未影响腹主动脉AUC,但降低肝脏kuptake(p < 0.001),使肝脏暴露显著降低27.3%(p < 0.001)。
- 利福平使肾脏kuptake显著降低,同时肾脏AUC降低30.4%(p < 0.001)。
- 利福平既未影响肺kuptake,也未影响肺AUC。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer. The wide inter-individual pharmacokinetic (PK) variability of erlotinib may impact treatment outcome and/or toxicity. Recent in vivo studies reported a nonlinear uptake transport of erlotinib into the liver, suggesting carrier-mediated system(s) to mediate its hepatobiliary clearance. Erlotinib has been identified in vitro as a substrate of organic anion-transporting polypeptide (OATP) transporters which expression does not restrict to hepatocytes and may impact the tissue uptake of erlotinib in vivo. RESULTS: The impact of rifampicin (40 mg/kg), a potent OATP inhibitor, on the liver uptake and exposure to tissues of 11C-erlotinib was investigated in rats (4 animals per group) using positron emission tomography (PET) imaging. Tissue pharmacokinetics (PK) and corresponding exposure (area under the curve, AUC) were assessed in the liver, kidney cortex, abdominal aorta (blood pool) and the lungs. The plasma PK of parent 11C-erlotinib was also measured using arterial blood sampling to estimate the transfer rate constant (kuptake) of 11C-erlotinib from plasma into different tissues. PET images unveiled the predominant distribution of 11C-erlotinib-associated radioactivity to the liver, which gradually moved to the intestine, thus highlighting hepatobiliary clearance. 11C-erlotinib also accumulated in the kidney cortex. Rifampicin did not impact AUCaorta but reduced kuptake, liver (p < 0.001), causing a significant 27.3% decrease in liver exposure (p < 0.001). Moreover, a significant decrease in kuptake, kidney with a concomitant decrease in AUCkidney (- 30.4%, p < 0.001) were observed. Rifampicin neither affected kuptake, lung nor AUClung. CONCLUSIONS: Our results suggest that 11C-erlotinib is an in vivo substrate of rOATP transporters expressed in the liver and possibly of rifampicin-inhibitable transporter(s) in the kidneys. Decreased 11C-erlotinib uptake by elimination organs did not translate into changes in systemic exposure and exposure to the lungs, which are a target tissue for erlotinib therapy.
引用
- Amor D, Goutal S, Marie S, et al. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. EJNMMI Res. 2018. PMID: 30116910. doi:10.1186/s13550-018-0434-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。